search
Back to results

Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau

Primary Purpose

Alzheimer Disease

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Lemborexant 25 mg
Placebo
Sponsored by
Brendan Lucey
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Alzheimer Disease focused on measuring poor sleep

Eligibility Criteria

60 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Age 60-80 years Any sex Any race/ethnicity Mini-Mental Status Examination score (MMSE) ≥ 27 Positive plasma amyloid-beta test (i.e., amyloid-positive) Pittsburgh Sleep Quality Index >5 Exclusion Criteria: Cognitive impairment as determined by history of MMSE < 27 Inability to speak or understand English Any sleep disorders other than insomnia No history of moderate-to-severe sleep-disordered breathing and STOP-Bang score > 5 History or reported symptoms suggestive of restless legs syndrome, narcolepsy or other sleep disorders No more than mild sleep apnea (AHI <16) on PSG Sleep schedule outside the range of bedtime 22:00-midnight Contraindication to lumbar catheter (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery) Cardiovascular disease requiring medication except for controlled hypertension (PI discretion) Stroke Hepatic or renal impairment Pulmonary disease (PI discretion) Type 1 diabetes HIV or AIDS Neurologic or psychiatric disorder requiring medication (PI discretion) Suicidal ideations Alcohol, tobacco or marijuana use (PI discretion) Use of sedating medications (PI discretion) Inability to get out of bed independently In the opinion of the investigator, the participant should be excluded due to an abnormal physical examination. Current pregnancy Body Mass Index >35 History of migraines (PI discretion) History of drug abuse in the last 6 months History or presence of any clinically significant medical condition, behavioral or psychiatric disorder (including suicidal ideation), or surgical history based on medical record or patient report that could affect the safety of the subject or interfere with study assessments or in the judgment of the PI participant is not a good candidate. Urinary or fecal incontinence Concurrently enrolled in another trial of an investigational drug or device

Sites / Locations

  • Washington University School of MedicineRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

treatment

placebo

Arm Description

20 participants will be randomized to take lemborexant 25mg at h.s for two consecutive nights

10 participants will be randomized to take placebo at h.s. for two consecutive nights.

Outcomes

Primary Outcome Measures

Change in CNS tau phosphorylation
Changes in CSF pT181/T181 ratio compared to placebo

Secondary Outcome Measures

Changes in other CSF AD biomarkers
Changes in CSF pS202/S202, pT217/T217, and amyloid-beta

Full Information

First Posted
February 5, 2023
Last Updated
June 27, 2023
Sponsor
Brendan Lucey
Collaborators
Eisai Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05728736
Brief Title
Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau
Official Title
Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 1, 2023 (Actual)
Primary Completion Date
March 2025 (Anticipated)
Study Completion Date
March 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Brendan Lucey
Collaborators
Eisai Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will look at the effects of lemborexant on Alzheimer's disease biomarkers found in the cerebrospinal fluid (CSF) and blood in individuals who are poor sleepers
Detailed Description
This study will determine the acute effect of lemborexant on CNS tau phosphorylation and other Alzheimer's disease biomarkers in individuals with poor sleep quality.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease
Keywords
poor sleep

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
treatment
Arm Type
Experimental
Arm Description
20 participants will be randomized to take lemborexant 25mg at h.s for two consecutive nights
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
10 participants will be randomized to take placebo at h.s. for two consecutive nights.
Intervention Type
Drug
Intervention Name(s)
Lemborexant 25 mg
Other Intervention Name(s)
Dayvigo
Intervention Description
Lemborexant 25mg will be taken nightly for two consecutive nights.
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
inactive pill, sugar pil
Intervention Description
Placebo will be taken nightly for two consecutive nights
Primary Outcome Measure Information:
Title
Change in CNS tau phosphorylation
Description
Changes in CSF pT181/T181 ratio compared to placebo
Time Frame
48 hours
Secondary Outcome Measure Information:
Title
Changes in other CSF AD biomarkers
Description
Changes in CSF pS202/S202, pT217/T217, and amyloid-beta
Time Frame
48 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age 60-80 years Any sex Any race/ethnicity Mini-Mental Status Examination score (MMSE) ≥ 27 Positive plasma amyloid-beta test (i.e., amyloid-positive) Pittsburgh Sleep Quality Index >5 Exclusion Criteria: Cognitive impairment as determined by history of MMSE < 27 Inability to speak or understand English Any sleep disorders other than insomnia No history of moderate-to-severe sleep-disordered breathing and STOP-Bang score > 5 History or reported symptoms suggestive of restless legs syndrome, narcolepsy or other sleep disorders No more than mild sleep apnea (AHI <16) on PSG Sleep schedule outside the range of bedtime 22:00-midnight Contraindication to lumbar catheter (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery) Cardiovascular disease requiring medication except for controlled hypertension (PI discretion) Stroke Hepatic or renal impairment Pulmonary disease (PI discretion) Type 1 diabetes HIV or AIDS Neurologic or psychiatric disorder requiring medication (PI discretion) Suicidal ideations Alcohol, tobacco or marijuana use (PI discretion) Use of sedating medications (PI discretion) Inability to get out of bed independently In the opinion of the investigator, the participant should be excluded due to an abnormal physical examination. Current pregnancy Body Mass Index >35 History of migraines (PI discretion) History of drug abuse in the last 6 months History or presence of any clinically significant medical condition, behavioral or psychiatric disorder (including suicidal ideation), or surgical history based on medical record or patient report that could affect the safety of the subject or interfere with study assessments or in the judgment of the PI participant is not a good candidate. Urinary or fecal incontinence Concurrently enrolled in another trial of an investigational drug or device
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cristina Toedebusch
Phone
314-747-0646
Email
toedebuschc@wustl.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Chloe Meehan
Phone
314-273-0878
Email
cmeehan@wustl.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Brendan Lucey, MD
Organizational Affiliation
Washington University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cristina Toedebusch, BS
Phone
314-747-0646
Email
toedebuschc@wustl.edu
First Name & Middle Initial & Last Name & Degree
Brendan Lucey, MD

12. IPD Sharing Statement

Learn more about this trial

Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau

We'll reach out to this number within 24 hrs